TL;DR: BSM Partners (2025) identifies a widening federal–state rift between the FDA and AAFCO over pet food ingredient definitions and labeling as a defining 2025 tension that is slowing new-ingredient launches across the industry.
Data note. This article is a review, not breaking news: the figures and market observations below are drawn from 2025 disclosures and reporting (see Sources) and are retained here as the historical record of that period. Read it as a retrospective on what happened and why it matters, not as a claim about current-quarter results.
fda aafco split: key facts
For decades, U.S. pet food regulation ran on a quiet partnership: the FDA set federal food-safety authority, while AAFCO (Association of American Feed Control Officials) produced the model ingredient definitions and labeling language that states adopted into law. In 2025, that partnership is fraying. According to BSM Partners (2025), the FDA–AAFCO split on ingredient and labeling rules is now a structural drag that slows the launch of new pet food ingredients—exactly the innovations (novel proteins, functional additives, sustainability inputs) the market is hungry for.
The headline: a federal–state rift slows launches
The core claim: the FDA–AAFCO divergence creates uncertainty that delays or blocks new-ingredient introductions (BSM Partners, 2025). A brand may satisfy one authority but trip the other, so legal and regulatory teams default to caution—and timelines stretch.
Who is who
- FDA (Center for Veterinary Medicine, CVM): federal authority over animal-food safety, ingredients, and claims.
- AAFCO: a member organization of state and federal feed officials that publishes ingredient definitions, labeling models, and the AAFCO Statement used on pet-food labels.
- State feed officials: adopt AAFCO models into state law, creating the patchwork FDA must navigate.
What the split is actually about
Ingredient definitions
AAFCO maintains a massive dictionary of approved ingredient names and definitions. When a novel ingredient (e.g., insect protein, cultured meat, algal oil, new botanical) arrives, it needs a definitional home. If FDA and AAFCO disagree on how to define or admit it, the path stalls.
Labeling and claims
“Human-grade,” “fresh,” “complete and balanced,” and functional claims all sit in a gray zone between AAFCO model language and FDA enforcement discretion. Divergence makes claim language legally risky.
Pace of updates
AAFCO’s definition process can lag innovation; FDA’s federal actions may outrun or conflict with state-adopted models. The mismatch is the rift.
Why this slows new-ingredient launches
Regulatory whiplash
A brand developing a novel protein must ask: Will FDA accept it? Will my state’s AAFCO-adopted law allow the label? If the answers diverge, launch is deferred.
Legal cost barrier
Smaller innovators lack the legal bandwidth to litigate or negotiate dual compliance, so they park the innovation or sell only in friendly jurisdictions.
Investor caution
Venture and strategic investors price in regulatory risk; a murky FDA–AAFCO landscape lowers the valuation and funding of ingredient-stage startups.
Premiumization bottleneck
Much 2025 growth is in functional and fresh products (soft-chew supplements at 42% of formats per NIQ, 2025; fresh dog food +13.4% per NIQ, 2025). These rely on novel ingredients—precisely what the split obstructs.
The innovation categories most affected
| Category | Example inputs | Impact |
|---|---|---|
| Novel proteins | Insect, cultured, alternative meats | High—definitional uncertainty |
| Functional additives | Botanicals, adaptogens, probiotics | Medium–high—claim ambiguity |
| Sustainability inputs | Algal, single-cell, upcycled | Medium—new definitions needed |
| Alternative binders/fats | New oils, fibers | Medium—label alignment |
Connections to other 2025 themes
H5N1
The H5N1 safety-plan mandate (BSM Partners, 2025; covered in our H5N1 piece) is FDA-driven and shows federal authority expanding—potentially widening the gap with AAFCO’s state-model world.
“The future is feline”
BSM’s feline thesis (covered in BSM insights) needs species-specific functional ingredients—again gated by the split.
M&A
Regulatory friction makes scaled, legally seasoned brands more attractive, feeding the 2025 M&A moderate year of mid-market consolidation.
Who wins and who loses
Winners
- Large CPG players (Mars, Nestlé, General Mills, Hill’s) with in-house regulatory teams.
- Established ingredients already in AAFCO/FDA harmony.
- States that harmonize quickly with federal signals.
Losers
- Ingredient startups lacking legal resources.
- Functional and fresh challengers needing novel inputs.
- Small brands wanting distinctive claims.
Possible paths forward
Realignment
FDA and AAFCO could renew a coordinated update process, clarifying which body owns what—reducing patchwork.
Federal preemption
Greater federal uniformity could preempt conflicting state models, speeding launches but shifting power to FDA.
Industry coalitions
Trade groups (e.g., PFI, NPA) may broker consensus definitions for high-priority novel ingredients.
Incremental state adoption
States could adopt updated AAFCO models faster, narrowing the gap even without federal action.
Market context: growth needs innovation
The split matters because the category is betting on innovation for growth:
- Global pet care ~$207B (2025) (Euromonitor, 2025).
- Global pet food ~$136.6B (IMARC, 2025), ~4.2% CAGR.
- Pet supplements $2.8B (USD Analytics, 2025), 8.1% CAGR—functionality demands new ingredients.
- CBD pet treats $1.15B (PMarketResearch, 2025), still awaiting clearer federal pathways.
If new ingredients cannot launch, these growth lanes narrow.
Risks of the status quo
- Innovation flight to friendlier jurisdictions (EU, APAC).
- Litigation over labeling claims multiplying.
- Consumer confusion from inconsistent labels across states.
- Competitive stagnation favoring incumbents over disruptors.
What to watch in 2025–2027
- Formal FDA–AAFCO statements of alignment or further divergence.
- State law updates adopting new AAFCO models.
- Novel-ingredient approvals (insect, cultured) finally clearing.
- Labeling-claim enforcement trends under FDA.
Historical context: how the partnership worked
The old model
For decades, AAFCO published ingredient definitions and the familiar “AAFCO Statement” (“complete and balanced…”) that appears on nearly every U.S. pet-food label. States adopted these into feed law, and FDA exercised federal oversight over safety and truthful labeling. The system was imperfect but workable because the two bodies moved in tandem.
Why it frayed
Several forces strained the model: a surge of novel ingredients outpacing definitional updates; FDA’s own enforcement priorities shifting; state budget constraints slowing AAFCO-model adoption; and high-profile safety debates (grain-free/DCM, raw/H5N1) pushing FDA toward more assertive federal action. The result is the 2025 rift BSM Partners flags.
Practical examples of the friction
“Human-grade” claims
Whether and how a pet food may say “human-grade” sits between AAFCO labeling models and FDA enforcement discretion. Brands risk state rejection or federal warning depending on wording—so many avoid the claim entirely, ceding differentiation.
Novel proteins and insects
Insect and cultured proteins need definitions before they can be labeled consistently. Until AAFCO and FDA align, a brand may legally sell in one state but not another, fragmenting launch strategy.
Functional and supplemental ingredients
Botanicals, probiotics, and behavioral supplements blur food and drug lines. The split leaves claims in limbo, exactly the gap functional-treat makers (soft-chew 42%, NIQ, 2025) must navigate.
What alignment could look like
A workable 2026+ model might: (1) designate FDA as the definitive ingredient authority with AAFCO as advisory; (2) accelerate definition updates via joint working groups; (3) preempt conflicting state models; and (4) publish a clear novel-ingredient fast-track. Until then, caution dominates and innovation lags.
Brand-level impact and case illustrations
A novel-protein startup’s dilemma
Imagine a startup with an insect-protein cat food. Under a unified system, it submits one dossier. Under the split, it may need AAFCO definition alignment and FDA comfort, plus 50 state-level variations. The legal spend alone can exceed early revenue—so the product stalls or launches only in friendly states, capping scale.
A legacy brand’s advantage
An established brand with existing AAFCO-listed ingredients faces little disruption; its labels remain valid. The split thus entrenches incumbents and raises the barrier for disruptors—a subtle anti-competition effect worth monitoring.
The functional-treat casualty
Functional treats (soft-chew 42%, NIQ, 2025) rely on botanical and supplemental claims. The labeling ambiguity directly suppresses their claim language, slowing the $2.8B supplements runway (USD Analytics, 2025).
International comparison
- EU: Centralized EFSA/Commission ingredient authorization—slower but unified.
- Canada: CFIA feeds regulations with provincial nuance—moderate.
- US: FDA federal + AAFCO state-model patchwork—the 2025 rift.
- China: National standards tightening—centralized but evolving.
The US system’s fragmentation is unique in granting states outsized power via AAFCO models, which is precisely why the federal–state split bites hardest here.
Who does what: FDA vs. AAFCO
- FDA (Center for Veterinary Medicine, CVM): The federal regulator. It enforces the Federal Food, Drug, and Cosmetic Act for animal food, approves food additives, and can mandate recalls.
- AAFCO: A non-governmental, state-member association. It publishes the Official Publication with ingredient definitions, labeling templates, and model bills that states voluntarily adopt into law.
The system works because states usually adopt AAFCO’s definitions, and FDA defers to them. The friction in 2025 is about who controls the definitions and how fast they update.
A worked example: the “human-grade” claim
The split shows up concretely in labeling fights. “Human-grade” pet food has been a flashpoint: AAFCO and FDA disagree on what the term legally requires, and states have sent warning letters to brands using it loosely. A brand confident its supply chain meets human-food standards may still face state-level pushback if AAFCO’s model language has not caught up. That gap — between what a brand can prove and what it can say — is the practical cost of misalignment.
The bigger context: “the future is feline”
BSM Partners’ 2025 list pairs the FDA–AAFCO split with two other themes: H5N1 pet-food safety (see our H5N1 article) and “the future is feline” — a recognition that cat food and cat-specific regulation are gaining strategic weight as the cat economy grows (Packaged Facts notes a “cat renaissance”; APPA data shows cat ownership rising).
The throughline: pet food is no longer a sleepy commodity category. It is a $136.6B global market (IMARC, 2025) where regulation, safety, and innovation collide — and the FDA–AAFCO relationship is the hinge.
Owner and industry verdict
On LinkedIn industry commentary (2025), the split is framed as a necessary growing pain: frustrating for innovators, but ultimately pushing toward clearer, safer rules. BSM Partners’ inclusion of it among the top insights signals that operators and investors are watching it as a market-shaping variable, not a footnote.
Related reading
- How H5N1 is reshaping pet food safety
- BSM Partners’ 2025 pet industry insights
- Functional pet treats and the soft-chew boom
FAQ
What is the FDA–AAFCO split?
It is the widening divergence between the FDA’s federal authority and AAFCO’s state-adopted ingredient/labeling models, creating conflicting compliance signals (BSM Partners, 2025).
How does the split slow pet food innovation?
Brands developing novel ingredients face uncertain approval across authorities, raising legal cost and delaying or blocking launches.
Which products are most affected?
Novel proteins (insect, cultured), functional additives, sustainability inputs, and distinctive label claims are most exposed.
Who benefits from the rift?
Large CPG players with regulatory teams and established ingredients benefit, while ingredient startups and small brands are disadvantaged.
Could the split be resolved?
Yes—via FDA–AAFCO realignment, federal preemption, industry coalitions, or faster state adoption of updated models.
Sources
- BSM Partners (2025): FDA–AAFCO split on ingredient/labeling rules slows new-ingredient launches.
- NIQ (2025): Functional soft-chew format 42%; fresh dog food +13.4% while total dog food −0.2%.
- Euromonitor (2025): Global pet care ~$207B in 2025.
- IMARC (2025): Global pet food ~$136.6B, ~4.2% CAGR.
- USD Analytics (2025): Pet supplements $2.8B, 8.1% CAGR.
- PMarketResearch (2025): CBD pet treats $1.15B.
